

# Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H1 2019

https://marketpublishers.com/r/M020A37B533EN.html

Date: April 2019

Pages: 61

Price: US\$ 3,500.00 (Single User License)

ID: M020A37B533EN

# **Abstracts**

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H1 2019

#### **SUMMARY**

According to the recently published report 'Macrophage Stimulating Protein Receptor - Pipeline Review, H1 2019'; Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) pipeline Target constitutes close to 7 molecules.

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Macrophage-stimulating protein receptor is a protein encoded by the MST1R gene. It regulates many physiological processes including cell survival, migration and differentiation. Upon ligand binding at the cell surface it induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules and interacts with the PI3-kinase subunit PIK3R1, PLCG1.

The report 'Macrophage Stimulating Protein Receptor - Pipeline Review, H1 2019' outlays comprehensive information on the Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.



It also reviews key players involved in Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 2 and 1 respectively.

Report covers products from therapy areas Oncology and Metabolic Disorders which include indications Breast Cancer, Gastric Cancer, Bile Duct Cancer (Cholangiocarcinoma), Colorectal Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Large Cell Lymphoma (ALCL), Anaplastic Thyroid Cancer, Clear Cell Squamous Cell Carcinoma, Colon Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Lung Cancer, Malignant Neoplasms, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Hodgkin Lymphoma, Osteolytic Bone Metastasis, Osteoporosis, Pancreatic Cancer, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Rhabdomyosarcoma, Solid Tumor and Uveal Melanoma.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

#### SCOPE

The report provides a snapshot of the global therapeutic landscape for Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1)

The report reviews Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages



The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics

#### **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading



companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



### **Contents**

Introduction

Global Markets Direct Report Coverage

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Overview

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Advenchen Laboratories LLC

Aslan Pharmaceuticals Ltd

Bristol-Myers Squibb Co

Eli Lilly and Co

Lead Discovery Center GmbH

Pfizer Inc

SignalChem Lifesciences Corp

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Drug Profiles

AL-2846 - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

ASLAN-005 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

BMS-777607 - Drug Profile

**Product Description** 



Mechanism Of Action

**R&D Progress** 

crizotinib - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

merestinib - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

Small Molecules to Antagonize RON Kinase for Pancreatic Cancer - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

Small Molecules to Inhibit MST1R for Oncology - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Dormant Products

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Discontinued Products

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Product Development Milestones Featured News & Press Releases

Nov 15, 2018: Crizotinib Plus Radiation May Reduce NF2-Related Hearing Loss Jul 26, 2018: NICE Issues Technology Appraisal Guidance on Crizotinib for Treating ROS1-positive Advanced NSCLC

Jun 11, 2018: Pfizer's Xalkori accepted for use in NHS Scotland

Jun 02, 2018: Updated Phase 1 results of crizotinib against MET-amplified non-small cell lung cancer

May 29, 2018: Pfizer's XALKORI (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications

Apr 15, 2018: Crizotinib Yielded a High Objective Response Rate for Adult Patients With ALK-positive Inflammatory Myofibroblastic Tumor

Apr 02, 2018: Lung cancer drug shows promise as targeted therapy for thousands with breast cancer

Feb 05, 2018: Adding crizotinib to radiation therapy may help preserve hearing in patients with NF2



Dec 08, 2017: Largest trial ever performed in alveolar soft part sarcoma: results published

Nov 14, 2017: XALKORI Approved by Health Canada for the Treatment of Patients with ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sep 20, 2017: Publication of EORTC 90101 "CREATE" Phase II trial

Sep 11, 2017: Pfizer Presents Overall Survival Data of XALKORI in Patients With ALK-positive Advanced Non-small Cell Lung Cancer

Aug 30, 2017: New approach to genetic testing matches lung cancer patient with lifesaving drug

Jun 02, 2017: OxOnc Announces that Co-development Partner Has Received Approval in Japan and Taiwan for Crizotinib (Xalkori) as a First-line Treatment for Patients with ROS1-Positive Non-Small Cell Lung Cancer

Feb 15, 2017: ASLAN Pharmaceuticals' new ASLAN002 (BMS777607) phase 1 data published in Science Translational Medicine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

**Expert Panel Validation** 

Contact Us

Disclaimer



# **List Of Tables**

#### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Advenchen Laboratories LLC, H1 2019

Pipeline by Aslan Pharmaceuticals Ltd, H1 2019

Pipeline by Bristol-Myers Squibb Co, H1 2019

Pipeline by Eli Lilly and Co, H1 2019

Pipeline by Lead Discovery Center GmbH, H1 2019

Pipeline by Pfizer Inc, H1 2019

Pipeline by SignalChem Lifesciences Corp, H1 2019

Dormant Projects, H1 2019

Discontinued Products, H1 2019



# **List Of Figures**

#### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

#### **COMPANIES MENTIONED**

Advenchen Laboratories LLC
Aslan Pharmaceuticals Ltd
Bristol-Myers Squibb Co
Eli Lilly and Co
Lead Discovery Center GmbH
Pfizer Inc
SignalChem Lifesciences Corp



#### I would like to order

Product name: Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185

Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H1 2019

Product link: https://marketpublishers.com/r/M020A37B533EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/M020A37B533EN.html">https://marketpublishers.com/r/M020A37B533EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



